12/22/2009 | CVHY | Hollis-Eden files $75 million shelf covering debt, stock, preferreds
|
11/9/2006 | PP | Market Commentary: Vasogen stock gives up 18% on $20.3 million unit sale; Spare Backup raises $4.33 million
|
11/8/2006 | BT | Market Commentary: Catalyst higher on debut; Hollis-Eden off 19% on PIPE; stem cell names better; Trimeris rises 23%
|
11/8/2006 | PP | Market Commentary: Hollis-Eden stock dives on $26 million direct stock deal; Lumera to close $16.95 million PIPE
|
11/8/2006 | BTPP | New Issue: Hollis-Eden to close $26 million direct stock placement
|
11/6/2006 | BT | Jefferies stops Hollis-Eden coverage at hold
|
11/3/2006 | BT | Market Commentary: Celgene sells $1 billion of stock; Hollis-Eden up amid Q3 net loss; Spectrum higher following earnings
|
11/3/2006 | BT | Hollis-Eden's cash use increases by $1.3 million, ends quarter with $47.4 million
|
10/13/2006 | BT | Market Commentary: Critical gains 5% on sale signals; Advancis warns, eyes new deal; Pharmacopeia rises 4% on PIPE
|
9/27/2006 | BT | Market Commentary: Nabi hires BofA, up after hours; Millennium off; BioSante dives 14.5%; BioCryst, Novavax gain
|
9/13/2006 | BT | Hollis-Eden: Preclinical data promising for compounds targeting prostate cancer
|
9/12/2006 | BT | Hollis-Eden says several drug candidates show anti-disease compounds
|
8/4/2006 | BT | Hollis-Eden Pharmaceuticals reports second-quarter net loss of $8.1 million
|
6/26/2006 | BT | Hollis-Eden included on HHS shortlist for treatment of radiation exposure
|
6/19/2006 | BT | Hollis-Eden may receive response from HHS on possible Neumune order before end of June
|
6/16/2006 | BT | Hollis-Eden: Preclinical data promising on anti-inflammatory steroids for lung inflammation
|
6/16/2006 | BT | Hollis-Eden Pharmaceuticals files $75 million shelf
|
6/16/2006 | BT | Market Commentary: Hollis-Eden stock jumps on positive preclinical data; Inspire to present results on cystic fibrosis drug
|
6/8/2006 | BT | Hollis-Eden to start hospital-acquired illness study with Neumune
|
5/17/2006 | BT | Hollis-Eden on hold by Jefferies
|
5/10/2006 | BT | Hollis-Eden reports net loss of $0.30 share
|
5/9/2006 | BT | Market Commentary: Hollis-Eden loses in advance of first-quarter report; Tercica dives 22% after close; Curis rises 17%
|
5/3/2006 | BT | Hollis-Eden files IND for phase 1 trials with Neumune in patients at risk of hospital-acquired infections
|
3/16/2006 | BT | Hollis Eden Pharmaceuticals says net loss widens to $29.4 million in 2005
|
2/24/2006 | BT | Hollis-Eden submits proposal for Acute Radiation Syndrome therapy
|
2/3/2006 | PP | Market Commentary: GOME Electrical finalizes $125 million convertible deal; Santarus gets $75 million equity line
|
2/2/2006 | PP | Market Commentary: Hollis-Eden procures agreements for $26 million direct stock deal; Dune Energy raises $23.85 million
|
2/2/2006 | BTPP | New Issue: Hollis-Eden gets agreements for $26 million direct placement
|
2/1/2006 | BT | Hollis-Eden remedies previous non-compliance with Nasdaq rule
|
1/30/2006 | BT | Jefferies maintains Hollis-Eden at hold
|
12/13/2005 | BT | Jefferies maintains Hollis-Eden at hold
|
11/4/2005 | BT | Jefferies ups Hollis-Eden to hold
|
10/3/2005 | BT | Hollis-Eden downgraded by Jefferies to underperform
|
8/3/2005 | BT | Hollis-Eden price target cut by Jefferies
|
7/8/2005 | BT | Market Commentary: BofA coverage boosts biotechs; Human Genome, other biodefense names mostly up; Transkaryotic firmer
|
7/8/2005 | BT | Hollis-Eden Pharmaceuticals files stock, warrant shelf
|
7/8/2005 | BT | Market Commentary: BofA coverage boosts biotechs; Human Genome, other biodefense names mostly up; Transkaryotic firmer
|
6/1/2005 | PP | New Issue: Hollis-Eden raises $10 million in direct placement of stock
|
6/1/2005 | PP | Market Commentary: Oil spike may hurt U.S. issuance, boost activity in Canada; Advanced Magnetics raises $13.8 million
|